Wang Liucan, Yu Min, Yang Hua
Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China.
J Inflamm Res. 2021 Apr 29;14:1701-1716. doi: 10.2147/JIR.S304101. eCollection 2021.
The effective colon drug delivery remains to be an international frontier research in inflammatory bowel disease (IBD) therapy. The exploration and research of nanocarrier-based nanomedicine with great potential brings new opportunities for IBD therapy and diagnoses. Functional nanocarriers with varying morphology and characteristics can not only effectively avoid the destruction of the complex gastrointestinal (GI) tract microenvironment but also endow drugs with target therapy and improved bioavailability, thus elevating therapeutic efficacy. In this review, we illustrated several challenges in IBD therapy, then emphasis on some latest research progress of nanoparticles based therapy of oral administration, rectal administration and parenteral administration, as well as IBD diagnoses. Finally, we described the future perspective of nanocarriers in the treatment and diagnoses of IBD.
有效的结肠药物递送仍是炎症性肠病(IBD)治疗领域的一项国际前沿研究。具有巨大潜力的基于纳米载体的纳米药物的探索和研究为IBD的治疗和诊断带来了新机遇。形态和特性各异的功能性纳米载体不仅能有效避免复杂胃肠道(GI)微环境的破坏,还能赋予药物靶向治疗能力并提高生物利用度,从而提升治疗效果。在本综述中,我们阐述了IBD治疗中的若干挑战,接着重点介绍了纳米颗粒在口服给药、直肠给药和胃肠外给药治疗以及IBD诊断方面的一些最新研究进展。最后,我们描述了纳米载体在IBD治疗和诊断中的未来前景。